ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.6 EUR | +2.86% |
|
+6.93% | 0.00% |
| 06-14 | Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup | DJ |
| 06-14 | Investors need more time to assess Fed comments |  |
| Sales 2024 * | 42.98B 40.16B 59.01B | Sales 2025 * | 52.62B 49.17B 72.25B | Capitalization | 791B 739B 1,086B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 11.15B 16.38B | Net income 2025 * | 16.55B 15.47B 22.73B | EV / Sales 2024 * | 18.8 x |
| Net Debt 2024 * | 18.07B 16.88B 24.81B | Net Debt 2025 * | 15B 14.01B 20.59B | EV / Sales 2025 * | 15.3 x |
| P/E ratio 2024 * |
65.7
x | P/E ratio 2025 * |
47.3
x | Employees | 43,000 |
| Yield 2024 * |
0.59% | Yield 2025 * |
0.68% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | +2.86% | ||
| 1 week | +6.93% | ||
| Current month | +10.20% | ||
| 1 month | +5.88% | ||
| 3 months | +18.03% |
1 week
20.60
21.60
1 month
18.4022.00
Current year
18.3025.20
1 year
18.3025.20
3 years
18.3025.20
5 years
18.3025.20
10 years
18.3025.20
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 21.6 | +2.86% | 0 |
| 24-06-13 | 21 | 0.00% | 0 |
| 24-06-12 | 21 | -1.87% | 0 |
| 24-06-11 | 21.4 | +2.88% | 0 |
| 24-06-10 | 20.8 | +2.97% | 0 |
Delayed Quote Deutsche Boerse AG, June 14, 2024 at 09:29 am
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.96% | 627B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 294B | |
| +18.02% | 245B | |
| +1.27% | 222B | |
| +11.95% | 215B | |
| +3.68% | 160B | |
| -4.38% | 157B |
- Stock Market
- Equities
- LLY Stock
- LLY0 Stock
